Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyphenamate SCHEMBL5704281 | 1.00 | KMT2A (0.42) | KMT2AMAPTCYP1A2SMN1; SMN2CYP2D6 | |
| SCHEMBL4590400 | 0.77 | MAPT (0.50) | KMT2AMAPTCYP1A2SMN1; SMN2CYP2D6 | |
| SCHEMBL5898588 | 0.77 | MAPT (0.46) | KMT2AMAPTCYP1A2SMN1; SMN2CYP2D6 | |
| Urethane SCHEMBL27979330 | 0.77 | ALOX15 (0.50) | KMT2AMAPTCYP1A2SMN1; SMN2CYP2D6 | |
| SCHEMBL10815680 | 0.75 | CA2 (0.43) | CYP1A2KCNN4CHRM3CYP2C9CYP2C19 | |
| SCHEMBL4307361 | 0.75 | CYP2C19 (0.56) | KMT2ACYP1A2SMN1; SMN2CYP2D6KCNN4 | |
| SCHEMBL5898545 | 0.75 | MAPT (0.43) | KMT2AMAPTCYP1A2CYP2D6KCNN4 | |
| SCHEMBL5704134 | 0.74 | LMNA (0.42) | KMT2ACYP1A2SMN1; SMN2LMNACHRM3 | |
| SCHEMBL7216196 | 0.74 | NPSR1 (0.44) | KMT2AMAPTCYP1A2SMN1; SMN2CYP2D6 | |
| Urethane SCHEMBL3680047 | 0.74 | ALOX15 (0.56) | KMT2AMAPTCYP1A2SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016196726-A9 | ANTI-TAU ANTIBODIES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-04-13 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-8110569-B2 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2007741-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | Xytis Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | ANVYL LLC | 2008-02-14 | — | — | US | claimed |
| US-20080039453-A1 | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use | OXFORD FINANCE CORPORATION | 2008-02-14 | — | — | US | claimed |
| WO-2007109288-A2 | ENANTIOMERICALLY PURE R-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007109289-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, CYP2C9, CYP3A5 | KMT2A 1976/4885MAPT 665/4885CYP1A2 60/4885 |
| US-20080039453-A1 | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, GRIK5, CYP3A5 | KMT2A 1795/4885MAPT 632/4885CYP1A2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.